AMR Action Fund Makes First Investment to Tackle Antibiotic Resistance

Antimicrobial resistance is a growing problem that has led to the emergence of bacteria resistant to most, if not all, known antibiotics. The AMR Action Fund was launched in 2021 by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) to sponsor the development of new antimicrobial drugs. The fund has just announce their first investments.

According to Phil Taylor of PharmaPhorum, “AMR Action Fund said this morning that the first two beneficiaries are Adaptive Phage Therapeutics (APT) and Venatorx Pharmaceuticals, two biotechs that according to AMR Action Fund chief executive Henry Skinner ‘are poised to change the treatment landscape for drug-resistant infections.’”

To read more, click here.

(Source: PharmaPhorum, April 4^th, 2022)